212 related articles for article (PubMed ID: 37535572)
1. System analysis identifies UBE2C as a novel oncogene target for adrenocortical carcinoma.
Huang R; Guo L; Chen C; Xiang Y; Li G; Zheng J; Wu Y; Yuan X; Zhou J; Gao W; Xiang S
PLoS One; 2023; 18(8):e0289418. PubMed ID: 37535572
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
3. Silencing ubiquitin-conjugating enzyme 2C inhibits proliferation and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma.
Wang X; Yin L; Yang L; Zheng Y; Liu S; Yang J; Cui H; Wang H
FEBS J; 2019 Dec; 286(24):4889-4909. PubMed ID: 31715067
[TBL] [Abstract][Full Text] [Related]
4. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
Gao Z; Man X; Li Z; Bi J; Liu X; Li Z; Zhu Y; Zhang Z; Kong C
Oncol Rep; 2019 Apr; 41(4):2440-2452. PubMed ID: 30816525
[TBL] [Abstract][Full Text] [Related]
6. UBE2C promotes the progression of head and neck squamous cell carcinoma.
Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
8. Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma.
Fu Y; Sun S; Bi J; Kong C; Yin L
Medicine (Baltimore); 2021 Mar; 100(10):e25031. PubMed ID: 33725886
[TBL] [Abstract][Full Text] [Related]
9. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
10. CENPF/CDK1 signaling pathway enhances the progression of adrenocortical carcinoma by regulating the G2/M-phase cell cycle.
Huang YG; Li D; Wang L; Su XM; Tang XB
J Transl Med; 2022 Feb; 20(1):78. PubMed ID: 35123514
[TBL] [Abstract][Full Text] [Related]
11. Identification of prognostic metabolic genes in adrenocortical carcinoma and establishment of a prognostic nomogram: A bioinformatic study.
Chen Q; Ren Z; Liu D; Jin Z; Wang X; Zhang R; Liu Q; Cheng W
Medicine (Baltimore); 2021 Dec; 100(50):e27864. PubMed ID: 34918636
[TBL] [Abstract][Full Text] [Related]
12. Identification of tumor-infiltrating immune cells and prognostic validation of tumor-infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real-world data.
Tian X; Xu W; Wang Y; Anwaier A; Wang H; Wan F; Zhu Y; Cao D; Shi G; Zhu Y; Qu Y; Zhang H; Ye D
Oncoimmunology; 2020 Jun; 9(1):1784529. PubMed ID: 32923148
[TBL] [Abstract][Full Text] [Related]
13. Identification of important invasion and proliferation related genes in adrenocortical carcinoma.
Alshabi AM; Vastrad B; Shaikh IA; Vastrad C
Med Oncol; 2019 Jul; 36(9):73. PubMed ID: 31321566
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis.
Li R; Pang XF; Huang ZG; Yang LH; Peng ZG; Ma J; He RQ
BMC Cancer; 2021 Sep; 21(1):996. PubMed ID: 34488675
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of ferroportin1 and ceruloplasmin predicts poor prognosis in adrenocortical carcinoma.
Zhu B; Zhi Q; Xie Q; Wu X; Gao Y; Chen X; Shi L
J Trace Elem Med Biol; 2019 Dec; 56():52-59. PubMed ID: 31442954
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Analyses of the Tumor Microenvironment Reveal That Ubiquitin-Conjugating Enzyme E2C Might Be a Potential Immunotherapy Target.
Huang GZ; Chen ZQ; Wu J; Shao TR; Zou C; Ai YL; Lv XZ
J Immunol Res; 2021; 2021():9250207. PubMed ID: 34950739
[TBL] [Abstract][Full Text] [Related]
17. Depletion of UBE2C reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.
Li J; Zhi X; Shen X; Chen C; Yuan L; Dong X; Zhu C; Yao L; Chen M
Biochem Biophys Res Commun; 2020 Mar; 523(2):434-440. PubMed ID: 31875843
[TBL] [Abstract][Full Text] [Related]
18. UBE2C affects breast cancer proliferation through the AKT/mTOR signaling pathway.
Lu ZN; Song J; Sun TH; Sun G
Chin Med J (Engl); 2021 Oct; 134(20):2465-2474. PubMed ID: 34620747
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of ubiquitin-proteasome system related genes as a prognostic signature for papillary renal cell carcinoma.
Zhang X; Liu X; Xiong R; An HX
Aging (Albany NY); 2022 Nov; 14(23):9599-9616. PubMed ID: 36385010
[TBL] [Abstract][Full Text] [Related]
20. UBE2C serves as a prognosis biomarker of uterine corpus endometrial carcinoma via promoting tumor migration and invasion.
Ma S; Chen Q; Li X; Fu J; Zhao L
Sci Rep; 2023 Oct; 13(1):16899. PubMed ID: 37803076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
